miR-709通过由GSK3B下调调节诱导的FGF2上调节来产生血管新生作用
Koji Ueno1,2, Hiroshi Kurazumi3, Ryo Suzuki3
1Department of Surgery and Clinical Science, Graduate School of Medicine, Yamaguchi University, Minami-Kogushi 1-1-1, Ube, Yamaguchi, 755-8505, Japan. kjueno@yamaguchi-u.ac.jp.
Scientific reports
|May 18, 2024
概括
研究人员将miR-709确定为治疗后肢缺血症的关键血管性微RNA (miRNA). 这种miRNA通过通过降低糖原合成激酶3β (GSK3B) 调节纤维细胞生长因子2 (FGF2) 的上调,促进血液流量的恢复.
科学领域:
- 心血管生物学 心血管生物学
- 分子医学是分子医学.
- 再生医学是一种再生医学.
背景情况:
- 后肢缺血是一种严重的疾病,需要新的治疗策略.
- 细胞外囊泡 (EV) 中的微RNA (miRNA) 显示出治疗缺血性疾病的潜力.
研究的目的:
- 确定用于治疗后肢缺血组织的特定血管性miRNA.
- 阐明有前途的治疗性miRNAs的作用机制.
主要方法:
- 在患有缺血症耐受性 (C57BL/6) 和不耐受性 (BALB/c) 的小鼠中分析了血衍生的EV和miRNA.
- 大动脉环测试以选血管性miRNA候选者.
- 在后肢缺血模型中对血液流量恢复的体内评估.
- 对基因表达 (FGF2,GSK3B) 和细胞效应的分子分析.
主要成果:
- 通过大动脉环测试,确定了43种血管性miRNA候选物,缩小到14种.
- miR-709显示出促进后肢缺血中血流恢复的显著潜力.
- 在EVs中封装的miR-709增加了缺血组织中的FGF2mRNA表达.
- miR-709降低了GSK3B的调节,导致FGF2表达和内皮细胞增殖的增加.
结论:
- miR-709是一种强大的血管性miRNA,用于治疗后肢缺血症.
- 该机制涉及miR-709针对GSK3B,随后升级FGF2.
- 通过EV介导的miR-709的输送代表了对缺血性疾病的有前途的治疗方法.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K